← All trials
NCT03838185
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2019
- Primary completion
- Oct 31, 2019
- Completion date
- Jan 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Abrexa Pharmaceuticals, Inc.Lead sponsor
- Vince & AssociatesOverall official - principal investigator
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.